ACIP recommends meningococcal vaccine for high-risk infants
Children as young as 9 months who are at high risk for invasive meningococcal disease should receive quadrivalent meningococcal vaccine, according to a new recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).
Children as young as 9 months who are at high risk for invasive meningococcal disease should receive quadrivalent meningococcal vaccine, according to a new recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).
High-risk infants include those with complement component deficiencies, those in a risk group for a community or institutional outbreak, and those traveling to areas where meningococcal disease is epidemic or highly endemic.
The vaccine would be administered to infants aged 9 to 23 months in 2 doses 3 months apart.
Last April, the US Food and Drug Administration (FDA) approved Menactra (Sanofi Pasteur; Swiftwater, Pennsylvania) quadrivalent meningococcal vaccine for use in children 9 months and older. The other FDA-approved quadrivalent meningococcal vaccine, Menveo (Novartis; Cambridge, Massachusettsd), has not been approved for children younger than 2 years. Both vaccines protect against the disease caused by Neisseria meningitidis serotypes A, C, Y, and W-135.
The new recommendation was adopted at ACIP’s June meeting in Atlanta. ACIP also voted to include the updated guidance in the Vaccines for Children program. The recommendation becomes official when approved by the CDC’s director and published in Morbidity and Mortality Weekly Report.
American Academy of Pediatrics. Meningococcal vaccine OK for high-risk infants: ACIP. AAP News. June 23, 2011; doi: 10.1542/aapnews.20110623-1.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
